On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future

References

• Gandhi UH, Cornell RF, Lakshman A, et al., Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 33(9): 2266–2275. 2019. DOI:10.1038/s41375-019-0435-7.
   PubMed Web of Science ®Google Scholar
• Podar K, Jager D. Targeting the immune niche within the bone marrow microenvironment: the rise of immunotherapy in multiple myeloma. Curr Cancer Drug Targets. 2017;17(9):782–805.
   PubMed Web of Science ®Google Scholar
• Verkleij CPM, Frerichs KA, Broekmans M, et al. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget. 2020;11(45):4076–4081. DOI:10.18632/oncotarget.27792.
   PubMedGoogle Scholar
• Zhou X, Einsele H, Danhof S. Bispecific antibodies: a new era of treatment for multiple myeloma. J Clin Med. 2020;9(7). DOI:10.3390/jcm9072166
   Web of Science ®Google Scholar
• Podar K, Leleu X. Relapsed/refractory multiple myeloma in 2020/2021 and beyond. Cancers. 2021;13(20). DOI:10.3390/cancers13205154
   Web of Science ®Google Scholar
• Kumar S, Rajkumar SV. BiTEing the tumor. J Clin Oncol. 2020;38(18):2077–2079.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Nahi H, Plesner T, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020;7(6):e447–e455. DOI:10.1016/S2352-3026(20)30081-8.
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34(7):1875–1884. DOI:10.1038/s41375-020-0711-6.
   PubMed Web of Science ®Google Scholar
• Weisel KC, Sonneveld P, Mateos M-V, et al. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients (pts) with multiple myeloma (MM): four-year update of castor. Blood. 2019;134(Supplement_1):3192. DOI:10.1182/blood-2019-123527.
   Google Scholar
• Sonneveld P, Terpos E, Boccadoro M, et al. Pomalidomide and dexamethasone with or without subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: updated analysis of the phase 3 apollo study. Blood. 2021;138(Supplement 1):2747. DOI:10.1182/blood-2021-146907.
   PubMedGoogle Scholar
• Dimopoulos M, Quach H, Mateos M-V, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–197. DOI:10.1016/S0140-6736(20)30734-0.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7(5):e370–e380. DOI:10.1016/S2352-3026(20)30070-3.
   PubMed Web of Science ®Google Scholar
• Chari A, Rodriguez-Otero P, McCarthy H, et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. Br J Haematol. 2021;192(5):869–878. DOI:10.1111/bjh.16980.
   PubMed Web of Science ®Google Scholar
• Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–2107. DOI:10.1016/S0140-6736(19)32556-5.
   PubMed Web of Science ®Google Scholar
• Moreau P, Dimopoulos M-A, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361–2371. DOI:10.1016/S0140-6736(21)00592-4.
   PubMed Web of Science ®Google Scholar
• Moreau P, Hulin C, Perrot A, et al., Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 22(10): 1378–1390. 2021. DOI:10.1016/S1470-2045(21)00428-9.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 395(10218): 132–141. 2020. DOI:10.1016/S0140-6736(19)32956-3.
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar SK, Plesner T, et al., Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 22(11): 1582–1596. 2021. DOI:10.1016/S1470-2045(21)00466-6.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):91. DOI:10.1038/s41408-020-00357-4.
   PubMed Web of Science ®Google Scholar
• Weisel K, Dimopoulos MA, San-Miguel J, et al. Impact of elotuzumab plus pomalidomide/dexamethasone on health-related quality of life for patients with relapsed/refractory multiple myeloma (RRMM): final data from the phase 2 ELOQUENT-3 Trial. Blood. 2021;138(Supplement 1):1662. DOI:10.1182/blood-2021-145310.
   Google Scholar
• Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and/or refractory multiple Myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39(10):1139–1149.
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Mai EK, Nievergall E, et al. Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible Multiple myeloma patients: the phase III GMMG-HD7 trial. Blood. 2021;138(Supplement 1):463. DOI:10.1182/blood-2021-145097.
   Google Scholar
• Anderson LD Jr., Kaufman JL, Laubach JP, et al. Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): a subgroup analysis of griffin. Blood. 2021;138(Supplement 1):2723. DOI:10.1182/blood-2021-148533.
   Google Scholar
• Sonneveld P, Broijl A, Gay F, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): a multicenter, randomized, phase III study (PERSEUS). Journal of Clinical Oncology. 2019;37(15_suppl): TPS8055-TPS8055. DOI:10.1200/JCO.2019.37.15_suppl.TPS8055.
   Web of Science ®Google Scholar
• Swan D, O’Dwyer ME, Cahill M, et al. Cybord-dara in newly diagnosed transplant-eligible multiple myeloma: follow up results from the 16-Bcni-001/Ctrial-IE 16-02 study show high rates of MRD negativity at end of treatment. Blood. 2021;138(Supplement 1):2756. DOI:10.1182/blood-2021-145530.
   Google Scholar
• Perrot A, Lauwers-Cances V, Touzeau C, et al. Daratumumab plus ixazomib, lenalidomide, and dexamethasone as extended induction and consolidation followed by lenalidomide maintenance in standard-risk transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (IFM 2018-01): a phase II study of the Intergroupe Francophone Du Myélome (IFM). Blood. 2021;138(Supplement 1):464. DOI:10.1182/blood.2020008229.
   PubMedGoogle Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2021;32(3):309–322. DOI:10.1016/j.annonc.2020.11.014.
   PubMed Web of Science ®Google Scholar
• Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. The Lancet Oncology. 2021;22(12):1705–1720. DOI:10.1016/S1470-2045(21)00535-0.
   PubMed Web of Science ®Google Scholar
• Landgren O, Hultcrantz M, Diamond B, et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the Manhattan nonrandomized clinical trial. JAMA Oncol. 2021;7(6):862–868. DOI:10.1001/jamaoncol.2021.0611.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone With minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2021; online ahead of print. DOI:10.1200/JCO.21.01935.
   PubMed Web of Science ®Google Scholar
• Kaiser MF, Hall A, Walker K, et al. Daratumumab, cyclophosphamide, bortezomib, lenalidomide, dexamethasone (Dara-CVRd), V-augmented autologous stem cell transplant (V-ASCT) and Dara-Vrd consolidation in ultra-high risk (UHiR) newly diagnosed myeloma (NDMM) and primary plasma cell leukemia (pPCL) compared with myeloma XI/XI+ trial treatment for Uhir MM: the UK optimum/muknine trial. Blood. 2021;138(Supplement 1):465.
   Google Scholar
• Usmani SZ, Kumar S, Plesner T, et al. Efficacy of daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma and impaired renal function from the phase 3 maia study based on lenalidomide starting dose. Blood. 2021;138(Supplement 1):1646. DOI:10.1182/blood-2021-146940.
   PubMedGoogle Scholar
• Mollee P, Reynolds J, Janowski W, et al. A randomized study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) versus VCD and daratumumab induction followed By daratumumab maintenance (VCDD) for the initial treatment of transplant-ineligible patients with multiple myeloma (AMaRC 03-16). Blood. 2021;138(Supplement 1):2728.
   Google Scholar
• Ninkovic S, Murphy NE, Sidiqi H, et al. Isatuximab rescue for inadequate response to lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: interim analysis of the phase II iril study of the Australian myeloma Research consortium (AMaRC 18-02). Blood. 2021;138(Supplement 1):1671. DOI:10.1182/blood-2021-151871.
   Google Scholar
• Wang J, Fu W, Bang S-M, et al. Progression-free survival outcomes by response status for bortezomib, Melphalan, and prednisone with or without daratumumab in newly diagnosed multiple myeloma: pooled subgroup analysis of octans and alcyone. Blood. 2021;138(Supplement 1):1648. DOI:10.1182/blood-2021-148937.
   PubMedGoogle Scholar
• Hou J, Fu W, Bang S-M, et al. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible patients with newly diagnosed multiple myeloma: pooled analysis of octans and alcyone. Blood. 2021;138(Supplement 1):1661. DOI:10.1182/blood-2021-146974.
   Google Scholar
• Ocio E, Perrot A, Bories P, et al. OAB-005: update of safety and efficacy of isatuximab short-duration fixed-volume infusion plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT. Clin Lymphoma Myeloma Leuk. 2021;21:S3–S4.
   Web of Science ®Google Scholar
• Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021;8(1):e45–e54. DOI:10.1016/S2352-3026(20)30354-9.
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Mai EK, Bertsch U, et al. Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple Myeloma: results from the randomized phase III GMMG-HD6 trial. Blood. 2021;138(Supplement 1):486. DOI:10.1182/blood-2021-147323.
   PubMedGoogle Scholar
• Dimopoulos MA, Terpos E, Boccadoro M, et al. Apollo: phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients (Pts) with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):5–6.
   Google Scholar
• He J, Berringer H, Heeg B, et al. Indirect treatment comparisons of daratumumab, pomalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone or bortezomib and dexamethasone in patients with difficult-to-treat relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):4083. DOI:10.1182/blood-2021-146044.
   Google Scholar
• Usmani SZ, Quach H, Mateos M-V, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23(1):65–76. DOI:10.1016/S1470-2045(21)00579-9.
   PubMed Web of Science ®Google Scholar
• McMillan A, Basu S, Karunanithi K, et al. Daratumumab, bortezomib and dexamethasone (DVd) at First relapse for patients with relapsed/ refractory multiple myeloma (RRMM): a UK myeloma research alliance (UK-MRA) real-world multicentre analysis. Blood. 2021;138(Supplement 1):4120. DOI:10.1182/blood-2021-147043.
   Google Scholar
• Orlowski RZ, Delimpasi S, Straub J, et al. Efficacy and safety of oral ixazomib (Ixa), intravenous (IV) daratumumab (Dara), and IV/oral dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1–3 prior therapies: results of the second interim analysis (IA2) of a phase 2 study. Blood. 2021;138(Supplement 1):1666. DOI:10.1182/blood.2020008187.
   PubMedGoogle Scholar
• Terpos E, Gavriatopoulou M, Katodritou E, et al. Safety and efficacy of daratumumab with ixazomib and dexamethasone in patients with one prior lenalidomide-based Regimen: outcomes of the phase 2 daria study. Blood. 2021;138(Supplement 1):2737. DOI:10.1182/blood-2021-153082.
   Google Scholar
• Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and/or refractory multiple myeloma: analysis of POLLUX and CASTOR. Journal of Clinical Oncology. 2021 April 01;39(10):1139–1149.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Otero P, Gonzalez De La Calle V, Sureda A, et al. Selinexor in combination with daratumumab-bortezomib and dexamethasone for the treatment of relapse or refractory multiple Myeloma: initial results of the phase 2, open-label, multicenter GEM-selibordara study. Blood. 2021;138(Supplement 1):1677. DOI:10.1182/blood-2021-147725.
   PubMedGoogle Scholar
• Bahlis NJ, Baz R, Harrison SJ, et al. Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol. 2021;39(32):3602–3612. DOI:10.1200/JCO.21.00443.
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Quach H, Baz R, et al. Safety and preliminary efficacy from the expansion cohort of a phase 1/2 study of venetoclax plus daratumumab and dexamethasone Vs Daratumumab Plus bortezomib and dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):817. DOI:10.1182/blood-2021-146043.
   Google Scholar
• Kastritis E, Terpos E, Symeonidis A, et al. Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: final analysis of the phase 2 dare study. Blood. 2021;138(Supplement 1):2729. DOI:10.1182/blood-2021-153075.
   Google Scholar
• Macro M, Touzeau C, Mariette C, et al. Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail RRMM patients. a multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM). Blood. 2021;138(Supplement 1):83. DOI:10.1182/blood-2021-148152.
   Google Scholar
• Richardson PG, Perrot A, San-Miguel J F, et al. Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM). J Clin Oncol. 2021;39(15_suppl):8017. DOI:10.1200/JCO.2021.39.15_suppl.8017.
   Web of Science ®Google Scholar
• Djebbari F, Vallance G, Basker N, et al. Efficacy outcomes of isatuximab with pomalidomide and dexamethasone are comparable to (ICARIA-MM) trial data: initial results of a UK-wide real-world study of relapsed myeloma patients. Blood. 2021;138(Supplement 1):1963. DOI:10.1182/blood-2021-145408.
   Google Scholar
• Moreau P, Parmar G, Prince M, et al. A multi-center, phase 1b study to assess the safety, pharmacokinetics and efficacy of subcutaneous isatuximab plus pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):2744. DOI:10.1182/blood-2021-147136.
   PubMedGoogle Scholar
• Dimopoulos M, Bringhen S, Anttila P, et al. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood. 2021;137(9):1154–1165. DOI:10.1182/blood.2020008209.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M-A, Dytfeld D, Grosicki S, et al. P-193: elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial. Clin Lymphoma Myeloma Leuk. 2021 October 01;21:S143–S144. DOI:10.1016/S2152-2650(21)02320-X.
   Web of Science ®Google Scholar
• Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33–46.
   PubMed Web of Science ®Google Scholar
• Khongorzul P, Ling CJ, Khan FU, et al. Antibody–drug conjugates: a comprehensive review. Molecular Cancer Research. 2020;18(1):3. DOI:10.1158/1541-7786.MCR-19-0582.
   PubMed Web of Science ®Google Scholar
• Radocha J, van de Donk NWCJ, Weisel K. Monoclonal antibodies and antibody drug conjugates in multiple myeloma. Cancers (Basel). 2021;13(7):1571.
   PubMed Web of Science ®Google Scholar
• Lonial S, Lee HC, Badros A, et al., Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21(2): 207–221. 2020. DOI:10.1016/S1470-2045(19)30788-0.
   PubMed Web of Science ®Google Scholar
• Weisel K, Hopkins TG, Fecteau D, et al. Dreamm-3: a phase 3, open-label, randomized study to evaluate the efficacy and safety of belantamab mafodotin (GSK2857916) monotherapy compared with pomalidomide plus low-dose dexamethasone (Pom/Dex) in Participants with relapsed/refractory multiple myeloma (RRMM). Blood. 2019;134(Supplement_1):1900.
   Web of Science ®Google Scholar
• Nooka AK, Manteca MVM, Bahlis N, et al. DREAMM-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma. SOHO Italy. 2020;12(Supplement):955.
   Google Scholar
• Callander NS, Ribrag V, Richardson PG, et al. DREAMM-5 study: investigating the synergetic effects of belantamab mafodotin plus inducible T-cell co-stimulator agonist (aICOS) Combination therapy in patients with relapsed/refractory multiple myeloma. 653. myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: immune therapy for multiple myeloma. Blood. 2021;138(Supplement 1):897.
   Google Scholar
• Popat R, Nooka A, Stockerl-Goldstein K, et al. DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (Belamaf) in combination with Bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):19–20. DOI:10.1182/blood-2020-139332.
   Google Scholar
• Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021;138(Supplement 1):2736. DOI:10.1182/blood-2021-152241.
   Google Scholar
• Rifkin RM, Boyd K, Grosicki S, et al. DREAMM-7: a phase III study of the efficacy and safety of belantamab mafodotin (Belamaf) with bortezomib, and dexamethasone (B-Vd) in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):53–54. DOI:10.1182/blood-2020-139181.
   Web of Science ®Google Scholar
• Trudel S, Davis R, Lewis NM, et al. DREAMM-8: a phase III study of the efficacy and safety of belantamab Mafodotin with pomalidomide and dexamethasone (B-Pd) Vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):4. DOI:10.1182/blood-2020-139785.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Alonso Alonso A, Quach H, et al. DREAMM-9: phase I study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma. Blood. 2021;138(Supplement 1):2738. DOI:10.1182/blood-2021-153315.
   Google Scholar
• Hultcrantz M, Kleinman D, Ghataorhe P, et al. Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14. Blood. 2021;138(Supplement 1):1645. DOI:10.1182/blood-2021-152224.
   PubMedGoogle Scholar
• Trudel S, McCurdy A, Sutherland HJ, et al. Part 1 results of a dose-finding study of belantamab mafodotin in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM). Blood. 2021;138(Supplement 1):1653. DOI:10.1182/blood-2021-147101.
   PubMedGoogle Scholar
• Hultcrantz M, Orozco J, Peterson TJ, et al. Belantamab mafodotin in patients with relapsed/refractory Multiple myeloma, a real-world experience. Blood. 2021;138(Supplement 1):1644. DOI:10.1182/blood-2021-153443.
   Google Scholar
• Vaxman I, Abeykoon JP, Dispenzieri A, et al. “Real-Life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma- the mayo clinic experience. Blood. 2021;138(Supplement 1):1639. DOI:10.1182/blood-2021-147925.
   Google Scholar
• Alegre A, Benzo Callejo G, Alonso Fernández R, et al. Compassionate use of belantamab mafodotin for treatment of patients with relapsed/refractory multiple myeloma heavily treated. Spanish Experience. Blood. 2021;138(Supplement 1):3775.
   Google Scholar
• Atieh T, Atrash S, Mohan M, et al. Belantamab in combination with dexamethasone in patients with triple-class relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):1642. DOI:10.1182/blood-2021-149791.
   PubMedGoogle Scholar
• Abeykoon JP, Vaxman L, Patel SV, et al. Ocular toxicity of commercially available belantamab mafodotin in patients with advanced multiple myeloma. Blood. 2021;138(Supplement 1):2711. DOI:10.1182/blood-2021-154183.
   Google Scholar
• Lee HC, Raje NS, Landgren O, et al. Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia. 2021;35(1):255–258. DOI:10.1038/s41375-020-0834-9.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Migkou M, Bhutani M, et al. Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed/refractory multiple myeloma. Blood. 2020;136(Supplement 1):26–27. DOI:10.1182/blood-2020-136375.
   Google Scholar
• Jagannath S, LT H Jr, Ailawadhi S, et al. Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and/or refractory multiple myeloma. Clin Lymphoma, Myeloma Leuk. 2019;19(6):372–380. DOI:10.1016/j.clml.2019.02.006.
   PubMed Web of Science ®Google Scholar
• Kelly KR, Ailawadhi S, Siegel DS, et al. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. Lancet Haematol. 2021;8(11):e794–e807. DOI:10.1016/S2352-3026(21)00208-8.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Kaye FJ, Spigel DR, et al. Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease. Clin Lung Cancer. 2017;18(1):68–76.e2. DOI:10.1016/j.cllc.2016.09.002.
   PubMed Web of Science ®Google Scholar
• Ailawadhi S, Kelly KR, Vescio RA, et al. A phase I study to assess the safety and pharmacokinetics of Single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and/or refractory CD–56-positive multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(1):29–34. DOI:10.1016/j.clml.2018.08.018.
   PubMed Web of Science ®Google Scholar
• Vij R, Nath R, Afar DEH, et al. First-in-human phase I study of ABBV-838, an antibody–drug conjugate targeting SLAMF7/CS1 in patients with relapsed and refractory multiple myeloma. Clinical Cancer Research. 2020;26(10):2308–2317. DOI:10.1158/1078-0432.CCR-19-1431.
   PubMed Web of Science ®Google Scholar
• Manier S, Ingegnere T, Escure G, et al. Current state and next-generation CAR-T cells in multiple myeloma. Blood Rev. 2022;100929.
   Google Scholar
• Shah N, Aiello J, Avigan DE, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer. 2020;8(2):e000734.
   PubMed Web of Science ®Google Scholar
• Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE) and the European haematology association (EHA). Ann Oncol. 2022;33(3):259–275. DOI:10.1016/j.annonc.2021.12.003.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New Engl J Med. 2021 February 25;384(8):705–716.
   PubMed Web of Science ®Google Scholar
• Little JS, Shah P, Sperling AS, et al. Infectious complications in patients treated with idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood. 2021;138(Supplement 1):3839. DOI:10.1182/blood-2021-153942.
   Google Scholar
• Shah N, Munshi NC, Berdeja JG, et al. Baseline correlates of complete response to idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy in patients with relapsed and Refractory multiple myeloma: subanalysis of the KarMMa trial. Blood. 2021;138(Supplement 1):1739. DOI:10.1182/blood-2021-148375.
   Web of Science ®Google Scholar
• Cowan AJ, Pont M, Sather BD, et al. Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase bcma surface expression in patients with relapsed or refractory multiple myeloma. Blood. 2019;134(Supplement_1):204. DOI:10.1182/blood-2019-129405.
   Google Scholar
• Pont MJ, Hill T, Cole GO, et al. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585–1597. DOI:10.1182/blood.2019000050.
   PubMed Web of Science ®Google Scholar
• Raje NS, Shah N, Jagannath S, et al. Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and Refractory multiple myeloma. Blood. 2021;138(Supplement 1):548. DOI:10.1182/blood-2021-146518.
   Web of Science ®Google Scholar
• Martin T, Usmani SZ, and Berdeja JG, et al. Updated results from CARTITUDE-1: phase 1b/2Study of ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):549. DOI:10.1182/blood-2021-146060.
   Google Scholar
• Cohen YC, Cohen AD, Delforgo M, et al. Efficacy and safety of ciltacabtagene autoleucel (Cilta-cel), a B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1–3 prior lines of therapy: updated results from CARTITUDE-2. Blood. 2021;138(Supplement 1):3866.
   Google Scholar
• Hari P, Berdeja JG, De Stefano V, et al. Meta-analysis of ciltacabtagene autoleucel versus physician’s choice in the treatment of patients with relapsed or refractory multiple myeloma. Blood. 2021;138(Supplement 1):1676. DOI:10.1182/blood-2021-146177.
   Web of Science ®Google Scholar
• Mateos M-V, Weisel K, Martin T, et al. Ciltacabtagene autoleucel for triple-class exposed multiple myeloma: adjusted comparisons of CARTITUDE-1 patient outcomes versus therapies from real-world clinical practice from the LocoMMotion prospective study. Blood. 2021;138(Supplement 1):550. DOI:10.1182/blood-2021-146200.
   Web of Science ®Google Scholar
• Chen W, Fu C, Cai Z, et al. Sustainable efficacy and safety results from lummicar study 1: a phase 1/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in Chinese subjects with relapsed and/or refractory multiple myeloma. Blood. 2021;138(Supplement 1):2821. DOI:10.1182/blood-2021-150124.
   Google Scholar
• Kumar SK, Baz RC, Orlowski RZ, et al. Results from lummicar-2: a phase 1b/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and/or refractory multiple myeloma. Blood. 2020;136(Supplement 1):28–29. DOI:10.1182/blood-2020-139802.
   Web of Science ®Google Scholar
• Fu C, Jiang S, Jin J, et al. Integrated analysis of B-cell maturation antigen-specific CAR T cells (CT053) in relapsed and refractory multiple myeloma subjects by high-risk factors. Blood. 2021;138(Supplement 1):1751. DOI:10.1182/blood-2021-151935.
   Google Scholar
• Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood. 2021;137(21):2890–2901. DOI:10.1182/blood.2020008936.
   PubMed Web of Science ®Google Scholar
• de Larrea C F, Gonzalez-Calle V, Cabañas V, et al. Results from a pilot study of ARI0002h, an academic BCMA-directed CAR-T cell therapy with fractionated initial infusion and booster dose in patients with relapsed and/or refractory multiple myeloma. Blood. 2021;138(Supplement 1):2837. DOI:10.1182/blood-2021-147188.
   Google Scholar
• Mikkilineni L, Manasanch EE, Natrakul D, et al. Treatment of patients with T cells expressing a fully-human anti-BCMA CAR with a heavy-chain antigen-recognition domain Caused high rates of sustained complete responses and relatively mild toxicity. Blood. 2021;138(Supplement 1):3837. DOI:10.1182/blood-2021-152688.
   Google Scholar
• Wang Y, Gao Y, Wang H, et al. A preliminary study on the safety and efficacy of a novel human BCMA-targeting CAR-T therapy in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):1735. DOI:10.1182/blood-2021-152651.
   Google Scholar
• Frigault MJ, Rosenblatt J, Raje NS, et al. Phase 1 study of CART-Ddbcma, a CAR-T therapy utilizing a novel synthetic binding domain for the treatment of subjects with relapsed and /or refractory multiple myeloma. Blood. 2021;138(Supplement 1):3832.
   Google Scholar
• Sperling AS, Nikiforow S, Nadeem O, et al. Phase I study of PHE885, a fully human BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma manufactured in <2 days using the T-chargetm platform. Blood. 2021;138(Supplement 1):3864.
   Google Scholar
• Mailankody S, Diamonte C, Fitzgerald L, et al. Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in Patients with relapsed or refractory multiple myeloma. Blood. 2021;138(Supplement 1):827. DOI:10.1182/blood-2021-153204.
   PubMed Web of Science ®Google Scholar
• Lancman G, Sastow DL, Cho HJ, et al. Bispecific antibodies in multiple myeloma: present and future. Blood Cancer Discov. 2021;2(5):423–433. DOI:10.1158/2643-3230.BCD-21-0028.
   PubMedGoogle Scholar
• Romano A, Storti P, Marchica V, et al. Mechanisms of action of the new antibodies in use in multiple myeloma. Front Oncol. 2021;11:684561.
   PubMedGoogle Scholar
• Caraccio C, Krishna S, and Phillips DJ, et al. Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions. Front Immunol. 2020;11. DOI:10.3389/fimmu.2020.00011.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Garfall AL, and van de Donk NWCJ, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 398(10301): 665–674. 2021. DOI:10.1016/S0140-6736(21)01338-6.
   PubMed Web of Science ®Google Scholar
• Moreau P, Usmani SZ, Garfall AL, et al. Updated results from majesTEC-1: phase 1/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):896. DOI:10.1182/blood-2021-147915.
   Google Scholar
• Rodriguez-Otero P, Dholaria B, Askari E, et al. Subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed/refractory multiple myeloma: results from a Phase 1b multicohort study. Blood. 2021;138(Supplement 1):1647. DOI:10.1182/blood-2021-148723.
   Google Scholar
• Sebag M, Raje NS, Bahlis NJ, et al. Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from magnetismm-1. Blood. 2021;138(Supplement 1):895. DOI:10.1182/blood-2021-150519.
   Google Scholar
• Zonder JA, Richter J, Bumma N, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1/2 first-in-human study in patients with relapsed/refractory multiple Myeloma (RRMM). Blood. 2021;138(Supplement 1):160. DOI:10.1182/blood-2021-144921.
   PubMedGoogle Scholar
• Madduri D, Rosko A, Brayer J, et al. REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;138(Supplement 1):291.
   Google Scholar
• Kumar S, D’Souza A, Shah N, et al. A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with Relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):900. DOI:10.1182/blood-2021-150757.
   Google Scholar
• Costa LJ, Wong SW, Bermúdez A, et al. First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with Relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134(Supplement_1):143. DOI:10.1182/blood-2019-122895.
   Google Scholar
• Kakiuchi-Kiyota S, Ross T, Wallweber HA, et al. A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma. Leukemia. 2022;36(4):1006–1014. online ahead of print. DOI:10.1038/s41375-021-01478-w.
   PubMed Web of Science ®Google Scholar
• Plesner T, Harrison SJ, Quach H, et al. A phase I study of RO7297089, a B-cell maturation antigen (BCMA)-CD16a bispecific antibody in patients with Relapsed/refractory multiple myeloma (RRMM). Blood. 2021;138(Supplement 1):2755. DOI:10.1182/blood-2021-147418.
   Google Scholar
• Krishnan AY, Minnema MC, Berdeja JG, et al. Updated phase 1 results from monumental-1: first-in-human study of talquetamab, a g protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):158. DOI:10.1182/blood-2021-146868.
   Google Scholar
• Trudel S, Cohen AD, Krishnan AY, et al. Cevostamab monotherapy continues to show clinically Meaningful activity and manageable safety in patients with heavily pre-treated Relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood. 2021;138(Supplement 1):157. DOI:10.1182/blood-2021-147983.
   Google Scholar
• Doucey M-A, Pouleau B, Estoppey C, et al. A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma. J Clin Oncol. 2021;39(15_suppl):8044. DOI:10.1200/JCO.2021.39.15_suppl.8044.
   Google Scholar
• Costa LJ, Hari P, Kumar SK, et al. Overall survival of triple class refractory, penta-exposed multiple myeloma (MM) patients treated with selinexor plus dexamethasone or conventional care: a combined Analysis of the STORM and mammoth studies. Blood. 2019;134(Supplement_1):3125. DOI:10.1182/blood-2019-124991.
   Google Scholar
• D’Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia. 2020;34(1):21–34.
   PubMed Web of Science ®Google Scholar
• Yan Z, Cao J, Cheng H, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. The Lancet Haematology. 2019;6(10):e521–e529. DOI:10.1016/S2352-3026(19)30115-2.
   PubMed Web of Science ®Google Scholar
• Li C, Mei H, Hu Y, et al. S826 improved efficacy and safety of a dual-targeting BCMA and CD38 for relapsed/refractory multiple myeloma from a phase I study. HemaSphere. 2019;3(S1):365–366. DOI:10.1097/01.HS9.0000561584.43449.b7.
   Google Scholar
• Mohammed T, and Mailankody S. “Off-the-shelf” immunotherapies for multiple myeloma. Semin Oncol. 2022;49:S0093–7754(22).
   PubMedGoogle Scholar
• Wu L, Seung E, Xu L, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nature Cancer. 2020 January 01;1(1):86–98.
   PubMedGoogle Scholar
• Liegel J, Weinstock M, and Rosenblatt J, et al. Vaccination as immunotherapy in hematologic malignancies. J Clin Oncol. 2021;39:JCO.20.01706.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–945. DOI:10.1182/blood.2020005288.
   PubMed Web of Science ®Google Scholar
• Laubach JP, Kaufman JL, Sborov DW, et al. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of Griffin after 24 months of maintenance. Blood. 2021;138(Supplement 1):79. DOI:10.1182/blood-2021-149024.
   Google Scholar
• Kaufman JL, Usmani SZ, San-Miguel J, et al. Four-year follow-up of the phase 3 pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and Dexamethasone (Rd) alone in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 2019;134(Supplement_1):1866. DOI:10.1182/blood-2019-123483.
   Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. New Engl J Med. 2016;375(8):754–766. DOI:10.1056/NEJMoa1606038.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Boccadoro M, et al. Apollo: phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) alone in patients (Pts) with Relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):5–6.
   Google Scholar
• Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022;23(3):416–427. DOI:10.1016/S1470-2045(22)00019-5.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. New Engl J Med. 2018;379(19):1811–1822. DOI:10.1056/NEJMoa1805762.
   PubMed Web of Science ®Google Scholar
• Anderson JLD, Munshi NC, Shah N, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results. J Clin Oncol. 2021;39(15_suppl):8016. DOI:10.1200/JCO.2021.39.15_suppl.8016.
   Web of Science ®Google Scholar
• Chari A, Hari P, Bahlis NJ, et al. Phase 1b results for subcutaneous talquetamab plus daratumumab in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):161. DOI:10.1182/blood-2021-148813.
   Google Scholar
• Hoffman JE, Lipe B, Melear J, et al. SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001). Blood. 2021;138(Suppl 1). DOI:10.1182/BLOOD-2021-146047.
   Google Scholar
• Moreau P, Meuleman N, Graham P, et al. TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Iberdomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma. Blood. 2021;138(Suppl 1):2745–2745. DOI:10.1182/BLOOD-2021-152395.
   Google Scholar